Details Research on Gastric Cancer - Frontier Pharma - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
"Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- ' ' -- Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. -- Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new t